Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

Update: 2018-12-09

Description

Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advanced NSCLC after initial systemic therapy & considers whether these results should shape clinical practice.

Comments

In Channel

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)

2019-03-0820:37

Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)

2019-03-0524:33

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

2018-12-2813:28

What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)

2018-12-2108:58

The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)

2018-12-1109:58

Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

2018-12-0909:53

The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)

2018-12-0406:39

The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)

2018-12-0209:42

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

2018-11-1604:13

Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)

2018-11-1408:04

Updated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)

2018-11-0807:22

IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)

2018-11-0607:19

"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)

2018-09-0709:09

Local Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)

2018-09-0415:37

TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)

2018-08-3103:40

Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)

2018-08-2901:35

What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)

2018-08-2702:47

New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)

2018-08-2403:03

Is PROSTVAC the Vaccine Therapy We've Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)

2018-08-2202:03

Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)

2018-08-2001:08

00:00

Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

#box-pro-ellipsis-176045789754937{-webkit-line-clamp:2;}Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)

Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)